Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19649847 | 0.84 | ALDH1A1 (0.41) | SMN1; SMN2MAPTKMT2AMAPK1ALDH1A1 | |
| SCHEMBL29739691 | 0.83 | ALDH1A1 (0.43) | MAPTKMT2AMAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL18334275 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2HRH4MAPTKMT2ATSHR | |
| SCHEMBL4675955 | 0.83 | HRH4 (0.56) | SMN1; SMN2HRH4MAPTKMT2AMAPK1 | |
| SCHEMBL29177180 | 0.83 | ALDH1A1 (0.43) | MAPTKMT2AMAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL1816828 | 0.81 | HRH4 (0.50) | SMN1; SMN2HRH4MAPTKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL5381742 | 0.81 | HRH4 (0.54) | SMN1; SMN2HRH4MAPTKMT2AMAPK1 | |
| SCHEMBL24309237 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2HRH4MAPTKMT2ATSHR | |
| SCHEMBL21262632 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2HRH4MAPTKMT2ATSHR | |
| SCHEMBL1724026 | 0.80 | KDM4E (0.51) | SMN1; SMN2MAPTTSHRALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | JAK2, JAK1, JAK3 | SMN1; SMN2 3735/4885HRH4 1635/4885MAPT 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.